Subscribe to Email Alerts
Menu
About Us
About INOVIQ
Market Opportunity
Board
The Team
Advisors
Partners
Distributors
Compliance
Careers
Technology
Our Science
NETs Biomarker Capture Platform
SubB2M Pan-Cancer Probe
BARD1 Biomarker Technology
hTERT ICC Assay
Intellectual Property
Publications
Business Development
Products
Our Products
hTERT ICC Test
EXO-NET® Pan-Exosome
Product Technology & Features
Workflow and Performance
Product Ordering
Resources
Pipeline
Development Pipeline
Investors
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
Conferences & Events
Media
INOVIQ in the News
Contact
Contact Us
Subscribe to Email Alerts
Publications
Heading &
Sub-heading can be edited through HQI
Technology
>
Publications
Our Science
NETs Biomarker Capture Platform
SubB2M Pan-Cancer Probe
BARD1 Biomarker Technology
hTERT ICC Assay
Intellectual Property
Publications
Business Development
Publications
Please
contact us
for further information about any of the key publications:
BARD1
Ratajska M, Matusiak M, Kuzniacka A, Wasag B, Brozek I, Biernat W, Koczkowska M, Debniak J, Sniadecki M, Kozlowski P, Klonowska K, Pilyugin M, Wydra D, Laurent G, Limon J,
Irminger-Finger
Cancer predisposing BARD1 mutations affect exon skipping and are associated with overexpression of specific BARD1 isoforms. Oncol Rep. 2015 Nov;34(5):2609-17.
André PA, Prêle CM, Vierkotten S, Carnesecchi S, Donati Y, Chambers RC, Pache JC, Crestani B, Barazzone-Argiroffo C, Königshoff M, Laurent GJ,
Irminger-Finger
BARD1 mediates TGF-β signaling in pulmonary fibrosis. Respir Res. 2015 Sep 29;16:118.
Irminger-Finger
I, Ratajska M, Pilyugin M. New concepts on BARD1: Regulator of BRCA pathways and beyond. Int J Biochem Cell Biol. 2016 Mar; 72:1-17.
Marzec KA, Martino-Echarri E,
Irminger-Finger
I, Henderson BR.
BARD1 splice variants display mislocalization in breast cancer cells and can alter the apoptotic response to cisplatin
. Cancer Lett. 2016 Jul 28;381(1):149-155.
hTERT
Allison DB, Sharma R, Cowan ML, VandenBussche CJ: Evaluation of Sienna Cancer Diagnostics hTERT antibody on 500 consecutive urinary tract specimens. Acta Cytologica 2018, DOI: 10.1159/000489181.
Lalla M, VandenBussche CJ, Huan G, Anderson P: The hTERT ICC Test as an Adjunct to Urine Cytology: A Longitudinal Follow-Up. Poster presented at ICC 2020: 22nd International Conference on Cytology London, United Kingdom during May 21-22, 2020.
NET
s
Carlos Salomon
,
Saumya Das
,
Uta Erdbrügger
,
Raghu Kalluri
,
Sai Kiang Lim
,
Jerrold M Olefsky
,
Gregory E Rice
,
Susmita Sahoo
,
W Andy Tao
,
Pieter Vader
,
Qun Wang
,
Alissa M Weaver
:
Extracellular Vesicles and Their Emerging Roles as Cellular Messengers in Endocrinology: An Endocrine Society Scientific Statement
.
Endocrine Reviews, June 2022.
Poster Presentation:
Differential detection of cancer-derived extracellular vesicles using combined antibody functionalized magnetic beads and infrared spectroscopy
, Thomas STEWART, Tamkin AHMADZADA, Sophia AMERENA-COWIE, Emily STEIN, Peter FRENCH, Gregory RICE, Michelle WOOD, Joonsup LEE, Elham HOSSEINI-BEHESHTI, Peter A. LAY, Georges E. GRAU
SubB2M
Day CJ, Paton AW, Higgins MA, Shewell LK, Jen FE-C, Schulz BL, Herdman BP, Paton JC, Jennings MP (2017). Structure aided design of a Neu5Gc specific lectin. Nature Scientific Reports; 7: 1495
Wang J, Shewell LK, Paton AW, Paton JC, Day CJ, Jennings MP (2018). Specificity and utility of SubB2M, a new N-glycolylneuraminic acid lectin. Biochemical and Biophysical Research Communications 500: 765-771
Shewell LK, Wang JJ, Paton JC, Paton AW, Day CJ, Jennings MP (2018). Detection of N-glycolylneuraminic acid biomarkers in sera from patients with ovarian cancer using an engineered N-glycolylneuraminic acid-specific lectin SubB2M. Biochemical and Biophysical Research Communications 507: 173-177.
https://doi.org/10.1016/j.bbrc.2018.11.001
Shewell LK, Day CJ, Kutasovic JR, Abrrahams JL, Wang J, Poole J, Niland C, Ferguson K, Saunus JM, Lakhani SR, von Itzstein M, Paton JC, Paton AW, Jennings MP.
N-glycolylneuraminic acid serum biomarker levels are elevated in breast cancer patients at all stages of disease.
bioRxiv (preprint Aug 2021). doi:
https://www.biorxiv.org/content/10.1101/2021.06.21.449179v2